RPS6KB1 and non-small cell lung carcinoma: The results of this study further validated the findings discovered in other cell lines, indicating the important role of S6K1 in acquired resistance to EGFR-TKIs, and S6K1 antagonists may be beneficial in overcoming EGFR-TKI resistance in NSCLC patients.